Precision Medicine and Genomic Technologies: From Biomarkers to Targeted Therapies

Ahmed Mohammed^*
*Correspondence: Ahmed Mohammed, Department of Biomedical Engineering, Gitam University, Vizag, India, Email:

Introduction

Precision medicine, also known as personalized medicine, is a paradigm shift in healthcare that aims to provide tailored medical treatments based on an individual's genetic profile, lifestyle and environmental factors. This approach recognizes that each patient is unique and their response to therapies can vary significantly. Genomic technologies play a crucial role in precision medicine by analyzing an individual's genetic information to identify disease biomarkers and develop targeted therapies. This article provides an overview of precision medicine and the application of genomic technologies in biomarker discovery, diagnosis, prognosis and the development of targeted therapies [1].

Genomic technologies in biomarker discovery

Next-Generation Sequencing (NGS): NGS technologies enable the rapid and cost-effective sequencing of an individual's entire genome or specific regions of interest. This approach has revolutionized biomarker discovery by identifying genetic variations associated with diseases, drug responses and treatment outcomes. For example, The Cancer Genome Atlas (TCGA) project has utilized NGS to identify genomic alterations in various cancers, leading to the identification of novel biomarkers for diagnosis and targeted therapy [2].

Genome-Wide Association Studies (GWAS): GWAS involves scanning the entire genome of a large population to identify genetic variations associated with a particular disease or trait. This approach has been instrumental in identifying common genetic variants that contribute to complex diseases such as diabetes, cardiovascular diseases and psychiatric disorders. For instance, a GWAS study by Ripke, et al. identified multiple genetic risk loci associated with schizophrenia, providing insights into the underlying biology of the disease and potential therapeutic targets.

Transcriptomics and gene expression profiling: Transcriptomics technologies, such as microarrays and RNA sequencing, enable the profiling of gene expression patterns in cells or tissues. These techniques have been utilized to identify gene expression signatures associated with specific diseases and treatment responses. For example, transcriptomic profiling to identify gene expression signatures that predict response to immunotherapy in cancer patients, aiding in treatment selection and personalized therapy.

Description

Genomic technologies in diagnosis and prognosis

Genetic testing and molecular diagnostics: Genetic testing involves the analysis of specific genes or genetic variations associated with diseases or drug responses. It allows for the identification of genetic predispositions, diagnosis of inherited disorders and prediction of disease progression. For example, genetic testing for BRCA1 and BRCA2 mutations has revolutionized the diagnosis and management of hereditary breast and ovarian cancer [3].

Liquid biopsies and Circulating Tumor DNA (ctDNA): Liquid biopsies involve the analysis of circulating tumor cells or cell-free DNA in blood samples. This non-invasive approach allows for the detection of genetic alterations in tumors, monitoring of treatment response and early detection of minimal residual disease. The utility of ctDNA analysis in identifying targetable mutations and monitoring treatment response in lung cancer patients.

Pharmacogenomics: Pharmacogenomics investigates how an individual's genetic variations influence drug responses and treatment outcomes. By analyzing genetic markers associated with drug metabolism, efficacy and toxicity, pharmacogenomics can guide personalized drug selection and dosage optimization. For instance, testing for HLA-B*57:01 before initiating abacavir treatment helps prevent severe hypersensitivity reactions in patients with HIV [4].

Genomic technologies in targeted therapies

Precision oncology and targeted cancer therapies: Genomic profiling of tumors allows for the identification of specific genetic alterations that drive cancer growth and progression. Targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, can selectively inhibit these aberrant pathways, leading to improved treatment outcomes. For example, the use of targeted therapies like imatinib has revolutionized the treatment of chronic myeloid leukemia.

Gene editing technologies: Gene editing technologies, such as CRISPR-Cas9, offer the potential to precisely modify disease-causing genetic mutations. These technologies hold promise for the development of curative therapies for genetic disorders. For instance, CRISPR-based approaches have shown potential in correcting mutations associated with diseases like sickle cell anemia and cystic fibrosis in preclinical studies [5].

Theranostics and companion diagnostics: Theranostics combines diagnostics and therapeutics, enabling the selection of targeted therapies based on molecular profiling [6]. Companion diagnostics, such as HER2 testing in breast cancer, identify patients who are likely to respond to specific therapies. This approach improves treatment outcomes by matching patients with the most effective treatments.

Conclusion

Precision medicine, empowered by genomic technologies, has revolutionized healthcare by enabling tailored treatments based on individual genetic profiles. Genomic technologies have facilitated biomarker discovery, improved diagnosis and prognosis and led to the development of targeted therapies. As these technologies continue to advance, precision medicine is poised to transform patient care, offering more effective and personalized treatments across a wide range of diseases.

References

1. Witt, Stephanie H., F. Streit, M. Jungkunz and J. Frank, et al. "Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia." Transl Psychiatry 7 (2017): e1155-e1155.

Google Scholar, Crossref, Indexed at

2. He, Si-Yu, Ying-Chun Li, Yong Wang and Hai-Lin Peng, et al. "Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis." World J Gastroenterol 28 (2022): 2920.

Google Scholar, Crossref, Indexed at

3. Wan, Jonathan CM, Charles Massie, Javier Garcia-Corbacho and Florent Mouliere, et al. "Liquid biopsies come of age: towards implementation of circulating tumour DNA." Nat Rev Cancer 17 (2017): 223-238.

Google Scholar, Crossref, Indexed at

4. Nakamura, Yoshiaki, Akihito Kawazoe, Florian Lordick and Yelena Y. Janjigian, et al. "Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm." Nat Rev Clin Oncol 18 (2021): 473-487.

Google Scholar, Crossref, Indexed at

5. Middleton, G., H. Robbins, F. Andre and C. Swanton. "A state-of-the-art review of stratified medicine in cancer: Towards a future precision medicine strategy in cancer." Ann Oncol 33 (2022): 143-157.

Google Scholar, Crossref, Indexed at

6. Faulkner, Eric, Anke-Peggy Holtorf, Christine Y. Liu and Hwee Lin, et al. "Being precise about precision medicine: What should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group." Value Health 23 (2020): 529-539.

Google Scholar, Crossref, Indexed at